Key Takeaways
Anixa Biosciences Inc. secured a Mexican patent for its breast cancer vaccine that provides intellectual property protection into 2040, after a Phase 1 trial showed the vaccine elicited an immune response in 74 percent of participants.
"Our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization," Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, said in a statement.
The new patent, No. 432748, covers the company’s vaccine targeting α-lactalbumin, a protein found in certain breast cancers. The completed Phase 1 study met all its primary endpoints, proving safe at its maximum tolerated dose. The 74 percent immune response was observed across all tested doses.
The patent issuance is a key step for Anixa as it prepares for a Phase 2 clinical trial. While the company’s stock (NASDAQ: ANIX) trades below its 200-day moving average, analysts have set price targets between $9 and $14, seeing potential upside as the vaccine advances.
The vaccine, developed in collaboration with and licensed from the Cleveland Clinic, uses a "retired" protein strategy. It immunizes against α-lactalbumin, a protein normally associated with lactation that can be aberrantly expressed in tumors, aiming to prevent tumor formation without harming healthy tissue. This patent adds to recent intellectual property gains, including a similar allowance in South Korea.
The company, which holds more cash than debt with a cash and investments balance of $14.2 million as of January 31, 2026, is operating with a quarterly net loss of $2.57 million. Securing international patents is critical to its strategy of partnering for late-stage development and commercialization. Investors will now watch for the initiation of the Phase 2 trial and any potential partnership announcements.
This article is for informational purposes only and does not constitute investment advice.
